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Background: Tumour cells show greater dependency on glycolysis so providing a sufficient and rapid energy supply
for fast growth. In many breast cancers, estrogen, progesterone and epidermal growth factor receptor-positive cells
proliferate in response to growth factors and growth factor antagonists are a mainstay of treatment. However, triple
negative breast cancer (TNBC) cells lack receptor expression, are frequently more aggressive and are resistant to
growth factor inhibition. Downstream of growth factor receptors, signal transduction proceeds via phosphatidylinositol
3-kinase (PI3k), Akt and FOXO3a inhibition, the latter being partly responsible for coordinated increases in glycolysis and
apoptosis resistance. FOXO3a may be an attractive therapeutic target for TNBC. Therefore we have undertaken a
systematic review of FOXO3a as a target for breast cancer therapeutics.
Methods: Articles from NCBI were retrieved systematically when reporting primary data about FOXO3a expression in
breast cancer cells after cytotoxic drug treatment.
Results: Increased FOXO3a expression is common following cytotoxic drug treatment and is associated with apoptosis
and cell cycle arrest. There is some evidence that metabolic enzyme expression is also altered and that this effect is also
elicited in TNBC cells. FOXO3a expression serves as a positive prognostic marker, especially in estrogen (ER) receptor
positive cells.
Discussion: FOXO3a is upregulated by a number of receptor-dependent and -independent anti-cancer drugs and
associates with apoptosis. The identification of microRNA that regulate FOXO3a directly suggest that it offers a
tangible therapeutic target that merits wider evaluation.
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ApoptosisBackground
Breast cancer is the third most frequent cancer world-
wide. Amongst women, it is the most common malig-
nancy, making up 21% of all new cancer diagnoses.
Survival rates have been steadily extending over the past
50 years, primarily due to improvements in diagnosis
and treatment.
The drivers of proliferation in breast cancer are also
the phenotypic drug targets; hormone (estrogen, proges-
terone and HER2) receptors are commonly overexpressed.
This knowledge has been harnessed in development of tar-
geted therapies for breast cancer patients which inhibit* Correspondence: h.r.griffiths@aston.ac.uk
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unless otherwise stated.hormone receptor activity and can be co-administered with
the conventional, but non-specific, radiation and chemo-
therapy. The earliest approved therapy for endocrine
related breast cancers was tamoxifen, an anti-estrogen re-
ceptor (ER)-targeting compound. These agents are com-
monly used alongside general chemotherapy that induces
DNA damage through agents such as cisplatin which act
to reduce the DNA damage repair response or anti-
angiogenic agents [1,2].
The highly aggressive triple negative breast cancer
(TNBC), with a prevalence of 15% of breast cancer cases
often presenting in younger patients, is characterised by
tumours that lack expression of ER, progesterone recep-
tor and HER2/neu and is associated with a poor clinical
prognosis [3]. There is no targeted treatment regime for
this type of breast cancer and many patients experienceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nosis, as well as a higher incidence and probability of
metastasis [4,5].
The forkhead box O (FOXO) family is activated by
and limits the negative consequences of oxidative stress,
metabolic dysregulation, growth factor withdrawal and
DNA damage. At a molecular level, FOXO3a can be
activated by an increased AMP/ATP ratio through phos-
phorylation catalysed by 5′ AMP-activated protein kin-
ase (AMPK) at six conserved sites, five of which are
located within the transactivation domain [6]. In re-
sponse to a reduced energy supply FOXO3a transcrip-
tion factors act as important regulators of cellular
proliferation, cell cycle arrest, apoptosis, autophagy and
metabolism [7,8].
Cancer cells may be distinguished from healthy cells in
part by their metabolic phenotype. Solid tumours are
often hypoxic and so express hypoxia-inducible factor 1
(HIF1), which increases expression of glycolytic en-
zymes, glucose transporters and inhibitors of mitochon-
drial metabolism allowing cellular adaptation through
reliance on glycolysis to produce ATP in low oxygen en-
vironments [9,10]. This is associated with an increased
cellular uptake of glucose in order to maintain energy
homeostasis and is largely mediated upstream through
PI3k-regulated FOXO transcription factors [11]. Re-
moval of growth factors increases nuclear localisation of
FOXO3a. Nuclear FOXO3a binds to P300, which then
detaches from its transcription factor complex with HIF1
so suppresses glycolytic enzyme expression.
Phosphatidylinositol 3-kinase (PI3k)-activated Akt in-
hibits the activity of FOXO3a by phosphorylation of key
residues, Thr32, Ser253 and Ser315; Akt-phosphorylated
FOXO3a is then chaperoned by 14-3-3 proteins so ob-
scuring FOXO3a-DNA binding sites and further pre-
venting its activity within the nucleus [12]. FOXO3a is
subsequently exported into the cytoplasm, ubiquitinated
and degraded via the proteasome. Stress-induced phos-
phorylation of 14-3-3 by c-Jun N-terminal kinase (JNK)
reduces 14-3-3 protein-FOXO3a binding capacity and
directly inhibits nuclear export of FOXO3a thereby in-
creasing transcriptional activity of FOXO3a [13]. Further
metabolic control of FOXO3a activity is achieved following
nuclear shuttling by acetylation and NAD+-dependent
deacetylation.
Genomic analysis of TNBC has revealed frequent asso-
ciations with mutations in class 1 PI3k which lies dir-
ectly upstream of FOXO3a [14]. Mutations within the
tumour suppressor PTEN, a negative regulator of Akt
activation, can result in constitutively active Akt and
inhibit FOXO3a, so promoting HIF1 expression, antioxi-
dant gene expression and an increase membrane transloca-
tion of glucose transporters and rate-limiting enzymes
such as phosphofructokinase-1 [15] (Figure 1).Down-regulation of FOXO3a activity is often seen in
cancers and ERK- or inhibitor κappa B kinase (IκKβ)-
mediated inhibition of FOXO3a has been shown to pro-
mote tumorigenesis [16,17]. Despite evidence for FOXO3a
down-regulation in breast cancer, the AMPK-FOXO3a
pathway is still inducible, providing a potential therapeutic
target for cancer chemotherapy which is independent
of receptor status [6]. This evidence highlights FOXO3a
as a potentially important target by cytotoxic drugs es-
pecially in receptor-negative cells. To investigate the
validity of this hypothesis, we have undertaken a system-
atic approach to analysis of the published literature which
describes the effects of breast cancer chemotherapeutic
agents on FOXO3a. The goal is to determine whether
FOXO3a represents a critical target of therapeutics used
in the treatment of breast cancer, and therefore whether
the evidence supports direct targeting of FOXO3a in
chemoresistant-resistant disease notably in TNBC.Results
The systematic search for relevant articles initially re-
trieved 148 articles. The 51 articles that met the inclusion
criteria were then analysed and categorised according
to the drug target (extracellular receptor; PI3k; AKT;
FOXO3a), and assessed for dependency on FOXO3a ac-
tivity. Twenty articles met these conditions and have
been analysed here (Figure 2).
Activation of growth factor receptors signals to pro-
mote tumour progression, cell survival and invasive
characteristics. ER-positive cells are reported to have
higher FOXO3a levels and increased apoptotic activity
with less invasive characteristics than ER-negative cells.
The ER status of breast tumours is an important indica-
tor of prognosis, and although ER signaling plays a
major role in tumour progression, ER-positive cancer is
also associated with better prognosis than ER-negative
breast cancers [18].
Following a systematic review of the literature, five
articles were retrieved which described the effects of
growth factor receptor inhibition on FOXO3a activity
(Table 1). The mechanisms of action of anti-cancer
agent classes upstream from FOXO3a are illustrated in
Figure 3.
Irrespective of the target receptor for each of the in-
hibitors, lapatinib and trastuzumab (epidermal growth
factor receptor; EGFR and/or EGFR2; HER2, respect-
ively), or whether it targeted receptor-associated tyrosine
kinase (gefitinib), FOXO3a was consistently activated
and translocated to the nucleus. Three studies confirmed
an increase in apoptotic gene expression and extent of
apoptosis [19-21] after anti-growth factor receptor anti-
body treatment. Only one study reported effects on meta-
bolic gene expression with a switch away from anabolic
Figure 1 FOXO3a regulation by Akt. Growth factors/hormone stimulate PI3k phosphorylation of Akt, FOXO3a is phosphorylated by Akt, 14-3-3
also binds FOXO3a DNA binding sites, further preventing its activity in the nucleus. It is then tagged for degradation via ubiquitination and then
degraded in a proteasome. Adapted from (Wilson, 2009 [49]).
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of angiogenic VEGF expression [23].
Downstream from ligand-receptor binding, receptor-
associated PI3k is activated and catalyses the production
of phosphatidyl inositol (PtdIns) 4,5 bisphosphate and
PtdIns 3,4,5 trisphosphate that act as second messengers,
and via PDK1 activation results in Akt phosphorylation.
The importance of PI3k for signal transduction is evi-
denced by the work of Reagan-Shaw et al. who showed ac-
tivation of FOXO3a and induction of apoptosis when PI3k
is knocked down [24]. The bisphosphonate, zoledronic
acid, originally used for osteoporosis management, is now
in clinical trials as a chemotherapeutic drug; it activates
FOXO3a and inhibits expression of the proangiogenic fac-
tor CCN1 (Table 2) [25]. Zoledronic acid when used as an
adjuvant to endocrine therapy in premenopausal womenwith hormone receptor-positive early breast cancer pro-
vides clinical benefit and is cost-effective [26].
The phosphorylation of Akt indirectly via PDK1 acti-
vation by PI3k increases Akt activity which, in turn,
phosphorylates FOXO3a. A number of small molecule
inhibitors of Akt were identified in the review as con-
sistently activating FOXO3a with subsequent arrest of
the cell cycle (via p21 cip1 and p27 kip1 expression, [27,28])
and induction of apoptosis (Bim, [29-33]); Table 3.
The majority of the small molecules did not target
AKT directly but mediated AKT activation via unknown
targets and other kinases such as JNK and P38. Effects
on expression of ER differed between inhibitors treat-
ments [27,34].
A number of regulatory (patho)-physiological microRNA
(miR) and small molecule activators have been shown to
Figure 2 Flowchart showing the retrieval and review of literature according to systematic criteria.
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and transcriptional activity (Table 4; [35-40]).
miR155, which is up-regulated in cancer, is a negative
regulator of FOXO3a and subsequently Bim and p27 kip1
expression, but inhibition of miR155 restores sensitivity
to apoptosis [35]. Similarly, miR96 suppressed expres-
sion through the 3′-UTR on the FOXO3a gene, resultsTable 1 Growth factor receptor antagonists consistently activ
First author (Year) Treatment Effect on FOXO3a (Activates/Ina
Hegde (2007) [22] Lapatinib Activates in responsive cell lines; m
P-FOXO3a and by microarray, BT47
effect in resistant cell lines; MDA-M
Karadedou (2012) [23] Lapatinib Activates in BT474 or SKBR3 measu
nuclear translocation.
Real PJ (2005) [20] Trastuzumab Activates in MB231 and SUM159, p
effusions; measured as nuclear tran
of FOXO3a.
Krol (2007) [19] Gefitinib Activates in BT474 and SKBR3, but
gefitinib-resistant lines MCF-7, MDA
MDA-MB-453. Measured as Thr32 P
nuclear translocation analysis.
McGovern (2009) [21] Gefitinib Activates in BT474 and SKBR3 but
gefitinib-resistant lines MCF-7, MDA
and MDA-MB-453. Measured as nu
and microarray.in down-regulation of p21cip1, p27kip1 and cyclin dependent
kinases [38]. Modulation of FOXO3a by anti-miR may
prove useful to promote apoptosis. Other small molecules
appear to modulate FOXO3a activity by regulating the ac-
tivity of FOX3a-regulating kinases such as IκKβ and MEK
so preventing FOXO3a phosphorylation, increasing its nu-
clear half-life and transcriptional activity.ated FOXO3a in sensitive breast cancer cells
ctivates) Cellular effects
easured as Thr32
4 and SKBr3. No
B-468 and T47D.
Decreased expression of glyceraldehyde-3-phosphate
dehydrogenase, enolase 1, pyruvate kinase and fatty
acid synthase expression in BT474 and SKBr3
Growth rate reduced in BT474 and SKBr3
red by FOXO3a Decreased expression of VEGF.
rimary breast
slocation
Up-regulation of Bnip1.
Increased sensitivity to apoptosis.
no effect in
-MB-231, and
-FOXO3a and
Cell cycle arrest predominantly at the G(0)-G(1) phase
and apoptosis.
not the
-MB-231,
clear FOXO3a
Increase in Bim, p27 kip1
Figure 3 Schematic illustration of mechanisms of action of chemotherapeutic agents used in breast cancer therapy upstream of
FOXO3a expression. Chemotherapeutic agents in green boxes increase FOXO3a expression/activity; those in red boxes decrease FOXO3a
expression/activity. CAV1 = caveolin 1, CDK1 = cyclin dependent kinase 1, ERK = Extracellular signal-regulated kinases, FAS-L = FAS ligand,
FAS = fatty acid synthase, FOXO3a – forkhead box O3a, GFR – growth factor receptor IκKβ – inhibitor kappa kinase beta, JNK - Jun N-terminal
kinases, PI3k - phosphatidylinositol 3-kinase, SIRT1 = sirtuin 1.
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There is a growing need for new drug targets in cancer
treatment. These should efficiently combine fewer side-
effects with lower likelihood of resistance development.
The multi-step growth factor, PI3k/PTEN, Akt and
FOXO3a pathway provides a potentially important target
network. Dysregulation of its components, such as
PTEN, PIK3CA, and AKT (PKB), are common in solid
tumours but despite evidence for FOXO3a down-
regulation in breast cancer, the AMPK-FOXO3a pathway
is still inducible.
This systematic review has highlighted that several dif-
ferent classes of drugs can increase FOXO3a activation
and promote apoptosis by targeting many of the key
steps in the pathway downstream of the receptor inTable 2 PI3k inhibition causes FOXO3a activation in breast ca
First author (Year) Treatment Effect on FOXO3a (Activ
Espinoza (2011) [25] Zoledronic acid (ZOL) Activates in MDA-MB-231
nuclear translocation of FO
Guo (2004) [34] Wortmannin, EGCG Activates in MCF-7 and ZR
MDA-MB-231 cells, measu
and nuclear translocation.breast cancer cell lines irrespective of hormone receptor
status. There is some evidence that metabolic pathways
are also affected when FOXO3a is targeted, favouring
oxidative phosphorylation rather than glycolysis. Our
systematic literature approach has largely retrieved pa-
pers published around FOXO3a effects on cell cycle
control and induction of apoptosis. The importance of
metabolic switching as a mechanism for FOXO3a up-
regulation in slowing growth of breast cancer cells has
been reported in one study only, probably because the
published studies have limited their focus to analysis of
death and death pathways.
Recently, a dual network strategy for therapeutic inter-
vention has been proposed to target various diseases
[41]; such an approach inhibits central nodes in diseasencer cells
ates/Inactivates) Cellular effects
and MCF-7 measured by
XO3a.
Inhibited proangiogenic factor, CCN1 in TNBC
-75 cells; and Hs578T and
red as FOXO3a expression
Increased ER expression
Table 3 AKT inhibition activates FOXO3a in breast cancer cells
First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates) Cellular effects
Brandi (2013) [27] Indole-3-carbinol cyclic tri- and tetrameric
derivatives, specific target unknown but
inhibits AKT directly or indirectly.
Activates in MCF-7 and MDA-MB-231 breast
cancer cell lines) and in vivo in a tumour
xenograft measured as nuclear translocation
of FOXO3a.
Increased expression of p21 cip1, p27 kip1
and decreased ER expression.
Li (2007) [29] Selenium and Doxorubicin via p38
mediated inhibition of AKT.
Activates in MCF7 measured by P-FOXO3a
and reporter assay.
Increased Bim expression and apoptosis.
Sharma (2012) [33] 18β-glycyrrhetinic acid (GRA) specific
target unknown but inhibits AKT directly
or indirectly.
Activates in MCF7 but not normal breast
cell line MCF-10 measured as increased
expression and nuclear translocation.
Increased Bim expression and
caspase-dependent apoptosis.
Sunters (2006) [32] Paclitaxel inhibits AKT via JNK Activates in MCF7 measured as nuclear
localisation of FOXO3a.
JNK1 activation and apoptosis in MCF7
and also in a panel of other cells lines
MT 3522, 734 B, ZR-75-1, T47-D, CAL-51,
CAMA-1, MDA-MB-231, and SKBR-7.
Xie (2010) [31] SZ-685C (marine anthraquinone) specific
target unknown. Inhibits AKT directly
or indirectly.
Activates in MCF-7 and MDA-MB-435. AKT inhibition.
Increased Bim.
Increased apoptosis.
Increased caspase activity.
Zhao (2013) [30] 5,7-dihydroxy-8-nitrochrysin (NOC)-specific
target unknown. Inhibits AKT directly
or indirectly.
Activates in MDA-MB-453. Increased Bim expression
Increased apoptosis.
Lin (2011) [28] FLOT1 silencing associated with
suppression of Akt activity
Activates in MCF7 and MDA-231 measured
as expression level and P-FOXO3a.
Up-regulation of p21 cip1 and p27 kip1
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ise that during disease progression the importance
of any given target may change and so may be best
approached using sequential multi-target therapy [41]. If
FOXO3a expression changes occur early in the lifecycle
of breast cancer, the metabolic switch through a
FOXO3a node may prove to be an important route to
delaying disease progression.
FOXO3a can inhibit expression of glycolytic enzymes
through HIF-1 inhibition and can regulate mitochondrial
gene expression, ACO2, LARS2, MRPLI2, OXNAP1 and
ATP5G1, which are typically down-regulated in hypoxiaTable 4 FOXO3a activation in breast cancer cells increases ap
First author (Year) Treatment Effect o
Kong (2010) [35] miR-155 Inhibits
expressio
Kong (2012) [36] AZD6244, indirectly as an ATP-uncompetitive
inhibitor of MEK ½
Activate
AZD624
Lam (2012) [37] Aqueous extract of Fagonia Activate
blot in M
Lin (2010) [38] miR-96 Inhibits
MDA-MB
measure
reporter
Liu (2012) [39] Arsenic trioxide Activate
transloca
Stan (2008) [40] Withaferin. Activate
and MD[42]. The combined effect is to starve hypoxic tumours
and prevent further growth ultimately leading to autoph-
agy and death.
FOXO3a expression is a positive prognostic marker
for breast cancer [43]. The activity of FOXO3a, which
regulates ERα expression, is likely to be responsible. The
expression of ERα is associated with a higher degree of
differentiation of tumours and lower speed of tumour
cell proliferation [44], it can activate the cell cycle pro-
gression through either genomic or non-genomic path-
ways [45], and estrogen-inducible genes can suppress
tumour progression [46]. However, ER knockdown resultsoptosis
n FOXO3a (Activates/Inactivates) Cellular effects
in BT-474 measured by protein
n.
Decreased Bim and p27 expression
decreased apoptosis.
s FOXO3a in MTDH knock-down,
4 resistant lines.
Increased apoptosis.
s FOXO3a measured by Western
CF7 and MDA231.
Cell cycle arrest and apoptosis.
in BT549, ZR-75-30, Bcap37,
231, MDA-MB435, MCF-7, SKBR3
d as FOXO3a expression and by
assay.
Down-regulation of p21 cip1, p27 kip1,
CDK and cyclin 1.
s in MCF7 measured as nuclear
tion and expression.
Decreased IKKB.
Increased apoptosis.
s in MCF-7 (estrogen-responsive)
A-MB-231.
Increased Bim expression.
Increased apoptosis.
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of increased FOXO3a expression suggesting that the nu-
clear receptor represents a crucial switch in FOXO3a con-
trol of breast cancer cell aggressiveness [18]. Stratification
of patients according to receptor positivity may be critical
to improve the benefit:risk ratio of targeting FOXO3a.
Low FOXO3a expression is associated with poor prog-
nosis in a number of other cancers including neuroblast-
oma, gastric adrenocarcinoma, hepatocarcinoma and
poor metastasis-free survival in renal cell carcinoma
[47-50]. In common with observations in breast cancer
cells, treatment of colon cancer cells with selenite in-
duced ROS-dependent, FOXO3a-mediated apoptosis [51].
Enhancing FOXO3a expression appears to be a relevant
to treatment for a number of cancers. One emerging
means of modulating FOXO3a expression therapeutically
is post-transcriptionally via specifically targeted miR.
In this review, we have identified two papers that report
the effects of specific miR which affect FOXO3a expres-
sion in breast cancer cells. It has been estimated that
there may be thousands of target genes for miR-155, al-
though significant overlap has been observed between
miR-155 targets and the molecular profile of mutant
p53-expressing breast tumours suggesting that this may
prove to be a particularly useful target with fewer side-
effects [52]. Far fewer genes have been has been de-
scribed as targets for miR-96 although existing works
share the common conclusion that interference with
miR-96 using antisense miRNA (antagomiR) molecules
increase apoptosis in breast cancer cells. More work is
needed before to understand potential off-target effects
before their potential as therapeutic targets for breast
cancer can be appreciated [53].
Chemotherapeutic drug resistance can limit the appli-
cation of many anti-cancer therapies. Acquired resist-
ance to lapatinib and trastuzumab frequently occurs in
breast cancer patients, possibly as a consequence of
FOXO3a de-repression and increased ER signaling [54],
however, this does present an opportunity for adjuvant
therapy with drugs such as tamoxifen that target ER.
Similarly, upregulation of HER3 is induced in a FOXO3a
dependent way which attenuates the beneficial effects of
PI3k inhibitors unless used in combination with HER2/3
antagonists [55]. Indeed preclinical data support the sug-
gestion that targeting of the PI3k/mTOR pathway in com-
bination with trastuzumab is beneficial in trastuzumab-
resistant breast cancer [56]. The studies highlighted here
show the potential for targeting the upregulation of
FOXO3a to overcome resistance to AZD6244 [35].
The clinical trials register lists two studies currently
underway which will assess FOXO3a status (albeit not as
primary endpoints) one using an ER antagonist with a
pan-class I PI3k inhibitor and the other using reparaxin,
an IL-8 receptor antagonist.Conclusion
The identification of new classes of FOXO3a inhibitors
offers a promising strategy for future anti-cancer drug
design by targeting a downstream node of the PI3k path-
way that is not commonly mutated in cancers. In the
age of personalised medicine and following the identifi-
cation of regulatory miR that target FOXO3a directly,
their inhibition as an adjunct therapy alongside conven-
tional cytotoxic and/or receptor antagonists in stratified
patient groups merits evaluation.
Methods
We have designed a systematic literature review to iden-
tify published studies describing the effects of anti-
cancer drugs on FOXO3a in: human cell lines or primary
cells from breast cancer patients and from immunohisto-
chemical analyses of tissue.
PubMed/Medline, Cochrane and Embase databases
were searched from 1 January 2014 to 1 April 2014.
Neither the Cochrane library nor Embase yielded relevant
results using specific search criteria. Therefore PubMed/
Medline was the database used for information, the
Boolean search terms are listed below: ((FOXO3a[All
Fields] OR (Forkhead[All Fields] AND Box[All Fields] AND
O3[All Fields])) OR (Forkhead[All Fields] AND Box[All
Fields] AND (“proteins”[MeSH Terms] OR “proteins”[All
Fields] OR “protein”[All Fields]) AND 3[All Fields])) AND
(“breast neoplasms”[MeSH Terms] OR (“breast”[All Fields]
AND “neoplasms”[All Fields]) OR “breast neoplasms”[All
Fields] OR (“breast”[All Fields] AND “cancer”[All Fields])
OR “breast cancer”[All Fields]).
Results were limited to peer-reviewed, English language
articles only. Reviews, meta-analyses, case reports, edito-
rials and letters lacking primary data were excluded.
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